COVID-19-Associated Pulmonary Mucormycosis
COVID-19-associated mucormycosis (CAM) emerged as an epidemic in certain parts of the world amidst the global COVID-19 pandemic. While rhino–orbital mucormycosis was well reported during the pandemic, in the absence of routine diagnostic facilities including lower airway sampling, pulmonary mucormyc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-07-01
|
| Series: | Journal of Fungi |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2309-608X/8/7/711 |
| _version_ | 1797405882980499456 |
|---|---|
| author | Vidya Krishna Nitin Bansal Jaymin Morjaria Sundeep Kaul |
| author_facet | Vidya Krishna Nitin Bansal Jaymin Morjaria Sundeep Kaul |
| author_sort | Vidya Krishna |
| collection | DOAJ |
| description | COVID-19-associated mucormycosis (CAM) emerged as an epidemic in certain parts of the world amidst the global COVID-19 pandemic. While rhino–orbital mucormycosis was well reported during the pandemic, in the absence of routine diagnostic facilities including lower airway sampling, pulmonary mucormycosis was probably under-recognized. In this review, we have focused on the epidemiology and management of COVID-19-associated pulmonary mucormycosis (CAPM). CAPM is a deadly disease and mortality can be as high as 80% in the absence of early clinical suspicion and treatment. While histopathological examination of tissue for angio-invasion and cultures have remained gold standard for diagnosis, there is an increasing interest in molecular and serological methods to facilitate diagnosis in critically ill patients and often, immune-suppressed hosts who cannot readily undergo invasive sampling. Combined medical and surgical treatment offers more promise than standalone medical therapy. Maintaining adequate glycemic control and prudent use of steroids which can be a double-edged sword in COVID-19 patients are the key preventative measures. We would like to emphasize the urgent need for the development and validation of reliable biomarkers and molecular diagnostics to facilitate early diagnosis. |
| first_indexed | 2024-03-09T03:17:39Z |
| format | Article |
| id | doaj.art-1d87edb408944fb399b53452a86eebae |
| institution | Directory Open Access Journal |
| issn | 2309-608X |
| language | English |
| last_indexed | 2024-03-09T03:17:39Z |
| publishDate | 2022-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Fungi |
| spelling | doaj.art-1d87edb408944fb399b53452a86eebae2023-12-03T15:15:51ZengMDPI AGJournal of Fungi2309-608X2022-07-018771110.3390/jof8070711COVID-19-Associated Pulmonary MucormycosisVidya Krishna0Nitin Bansal1Jaymin Morjaria2Sundeep Kaul3Institute of Infectious Diseases, Apollo Hospitals, Chennai 600006, IndiaDivision of Infectious Diseases, Rajiv Gandhi Cancer Institute, New Delhi 110085, IndiaDepartment of Respiratory Medicine, Royal Brompton and Harefield Hospital, Guy’s and St. Thomas Hospital NHS Foundation Trust, London UB9 6JH, UKDepartments of Respiratory Medicine and Intensive Care, Royal Brompton and Harefield Hospital, Guy’s and St. Thomas Hospital NHS Foundation Trust, London UB9 6JH, UKCOVID-19-associated mucormycosis (CAM) emerged as an epidemic in certain parts of the world amidst the global COVID-19 pandemic. While rhino–orbital mucormycosis was well reported during the pandemic, in the absence of routine diagnostic facilities including lower airway sampling, pulmonary mucormycosis was probably under-recognized. In this review, we have focused on the epidemiology and management of COVID-19-associated pulmonary mucormycosis (CAPM). CAPM is a deadly disease and mortality can be as high as 80% in the absence of early clinical suspicion and treatment. While histopathological examination of tissue for angio-invasion and cultures have remained gold standard for diagnosis, there is an increasing interest in molecular and serological methods to facilitate diagnosis in critically ill patients and often, immune-suppressed hosts who cannot readily undergo invasive sampling. Combined medical and surgical treatment offers more promise than standalone medical therapy. Maintaining adequate glycemic control and prudent use of steroids which can be a double-edged sword in COVID-19 patients are the key preventative measures. We would like to emphasize the urgent need for the development and validation of reliable biomarkers and molecular diagnostics to facilitate early diagnosis.https://www.mdpi.com/2309-608X/8/7/711mucormycosisfungal infectionsrespiratory infectionspulmonary mucorCOVID-19SARS CoV-2 |
| spellingShingle | Vidya Krishna Nitin Bansal Jaymin Morjaria Sundeep Kaul COVID-19-Associated Pulmonary Mucormycosis Journal of Fungi mucormycosis fungal infections respiratory infections pulmonary mucor COVID-19 SARS CoV-2 |
| title | COVID-19-Associated Pulmonary Mucormycosis |
| title_full | COVID-19-Associated Pulmonary Mucormycosis |
| title_fullStr | COVID-19-Associated Pulmonary Mucormycosis |
| title_full_unstemmed | COVID-19-Associated Pulmonary Mucormycosis |
| title_short | COVID-19-Associated Pulmonary Mucormycosis |
| title_sort | covid 19 associated pulmonary mucormycosis |
| topic | mucormycosis fungal infections respiratory infections pulmonary mucor COVID-19 SARS CoV-2 |
| url | https://www.mdpi.com/2309-608X/8/7/711 |
| work_keys_str_mv | AT vidyakrishna covid19associatedpulmonarymucormycosis AT nitinbansal covid19associatedpulmonarymucormycosis AT jayminmorjaria covid19associatedpulmonarymucormycosis AT sundeepkaul covid19associatedpulmonarymucormycosis |